Difference between revisions of "Bleomycin (Blenoxane)"
Warner-admin (talk | contribs) m (Text replacement - "Basal cell carcinoma (BCC)" to "Cutaneous basal cell carcinoma") |
Warner-admin (talk | contribs) m (Text replacement - "Squamous cell carcinoma (SCC)" to "Cutaneous squamous cell carcinoma") |
||
Line 18: | Line 18: | ||
*[[Penile cancer]] | *[[Penile cancer]] | ||
*[[Post-transplant lymphoproliferative disorder]] | *[[Post-transplant lymphoproliferative disorder]] | ||
− | *[[ | + | *[[Cutaneous squamous cell carcinoma]] |
*[[Testicular cancer]] | *[[Testicular cancer]] | ||
*[[Vascular sarcoma]] | *[[Vascular sarcoma]] | ||
Line 54: | Line 54: | ||
[[Category:Penile cancer medications]] | [[Category:Penile cancer medications]] | ||
[[Category:Post-transplant lymphoproliferative disorder medications]] | [[Category:Post-transplant lymphoproliferative disorder medications]] | ||
− | [[Category: | + | [[Category:Cutaneous squamous cell carcinoma medications]] |
[[Category:Testicular cancer medications]] | [[Category:Testicular cancer medications]] | ||
[[Category:Vascular sarcoma medications]] | [[Category:Vascular sarcoma medications]] |
Revision as of 19:40, 16 August 2018
General information
Class/mechanism: Exact mechanism unknown, but suspected to inhibit DNA synthesis, with some evidence inhibition of RNA and protein synthesis. When administered intrapleurally for malignant pleural effusion, bleomycin acts as a sclerosing agent.[1]
Route: IV, IM, SC, intrapleural
Extravasation: irritant or neutral, depending on reference
- 1 unit of bleomycin = 1 mg of bleomycin
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Adenocarcinoma of unknown primary
- Cutaneous basal cell carcinoma
- Diffuse large B-cell lymphoma
- Follicular lymphoma
- HIV-associated lymphoma
- Hodgkin lymphoma
- Hodgkin lymphoma, nodular lymphocyte-predominant
- Osteosarcoma
- Penile cancer
- Post-transplant lymphoproliferative disorder
- Cutaneous squamous cell carcinoma
- Testicular cancer
- Vascular sarcoma
Patient drug information
- Bleomycin (Blenoxane) patient drug information (Chemocare)[2]
- Bleomycin (Blenoxane) patient drug information (UpToDate)[3]
History of changes in FDA indication
- 7/31/1973: Initial FDA approval
Also known as
- Brand names: Blenoxane, Bleo, Bleocin, Bleocip, Bleopar, Bleowel
References
- Drugs
- Intracavitary medications
- Intramuscular medications
- Intravenous medications
- Subcutaneous medications
- Irritant chemotherapy
- Neutral chemotherapy
- DNA synthesis inhibitors
- Adenocarcinoma of unknown primary medications
- Cutaneous basal cell carcinoma medications
- Diffuse large B-cell lymphoma medications
- HIV-associated lymphoma medications
- Hodgkin lymphoma medications
- Hodgkin lymphoma, nodular lymphocyte-predominant medications
- Osteosarcoma medications
- Penile cancer medications
- Post-transplant lymphoproliferative disorder medications
- Cutaneous squamous cell carcinoma medications
- Testicular cancer medications
- Vascular sarcoma medications
- FDA approved in 1973
- WHO Essential Cancer Medicine